FierceBiotech1d
Eisai, Eli Lilly didn't disclose heightened brain injury risk to Alzheimer's trial patients: NYT
A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
STAT2d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
The Financial Express9h
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
FiercePharma2d
Red light, green light: England's NICE not sold on Lilly's Kisunla despite UK approval
Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...